Berberine: metabolic and cardiovascular effects in preclinical and clinical trials

Arrigo FG Cicero\textsuperscript{1}  
Sibel Ertek\textsuperscript{2}  
\textsuperscript{1}Internal Medicine, Aging and Kidney Diseases Department, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;  
\textsuperscript{2}Ufuk University, Medical Faculty, Dr Ridvan Ege Hospital, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey

Abstract: Berberine is a plant alkaloid with numerous biological activities. A large body of preclinical \textit{in vitro} and \textit{in vivo} studies support different pharmacological actions of berberine that could be potentially useful in the management of metabolic diseases associated with high cardiovascular disease risk, such as mixed hyperlipidemia, insulin resistance, metabolic syndrome, and type 2 diabetes. Moreover, it seems that berberine also exerts anti-inflammatory and antiproliferative effects that could play a role in the development of atherosclerosis and its clinical consequences. Recently, the metabolic effects of berberine have been demonstrated in humans, opening new perspectives for the use of this molecule in patient therapy. Larger and longer clinical studies need to be carried out to implement the definition of the therapeutic role of berberine in humans.

Keywords: berberine, cardiovascular disease, diabetes, cholesterol

Introduction

Atherosclerosis is by far the single most important pathological process in the development of cardiovascular diseases (CVD), which are the single most common cause of morbidity and mortality in developed countries.\textsuperscript{1} Moreover, while the relative rate of CVD in developing nations is lower than that of developed (“westernized”) nations, the absolute number of people with CVD in developing nations now exceeds that in the West because 75% of the world’s population live in developing nations.\textsuperscript{2}

The main risk factors of CVD are known and educating the population about these risk factors is associated with a significant reduction of CVD risk. This is particularly evident when hypercholesterolemia is treated: a 1 mmol/l decrease in low-density lipoprotein-cholesterol (LDL-C) is associated with a 20% risk reduction of CVD events.\textsuperscript{3} On the other hand, a large amount of residual CVD risk remains, even in patients adequately treated with the available antihypercholesterolemic drugs, mainly because of their limited action on lipid fractions other than LDL-C and on subclinical risk factors such as insulin resistance and overweight.\textsuperscript{4} Moreover, despite the best available treatments, a large number of patients at high risk for CVD events do not reach lipid targets suggested by the most widely accepted international guidelines for CVD prevention.\textsuperscript{5} Therefore, some patients refuse to continue the standard treatment because of intolerance\textsuperscript{6} or search for alternative treatments because of the fear of statin-related side effects.\textsuperscript{7}

In this context, the aim of our review is to evaluate the metabolic properties of the natural alkaloid, berberine, and its potential application to CVD prevention.
We searched for all references available on PubMed and EMBASE using the following keywords: berberine, cholesterol and/or triglycerides, glucose, insulin, blood pressure, and atherosclerosis. We cross-matched the references with those cited in the available papers and included the most relevant in this review.

**Berberine sources and chemical characteristics**

Berberine is a plant quaternary ammonium salt from the group of isoquinoline alkaloids (2,3-methylenedioxy-9,10-dimethoxyprotoberberine chloride; C_{20}H_{18}NO_{4}) with a molar mass of 336.36122 g/mol. It is highly concentrated in the roots, rhizomes, and stem bark of various plants including Coptis chinensis (Huanglian), Rhizoma coptidis, Hydrastis canadensis (goldenseal), Berberis aquifolium (Oregon grape), Berberis vulgaris (barberry), Berberis aristata (tree turmeric), Tinospora cordifolia, Coptis rhizome, Arcangelisia flava, and Cortex rhellodendri (Figure 1). Berberine is yellow-colored, which is why in earlier times Berberis species were used to dye wool, leather, and wood. Wool is still dyed with berberine in Northern India. Under ultraviolet light, berberine shows a strong yellow fluorescence. As a natural dye, berberine has a color index (CI) of 75160.

As a drug, it is traditionally used for its supposed antimicrobial effects and as treatment of diabetes in traditional Chinese, Indian, and Middle-East folk medicine. Its chemical structure has a quaternary base and it is commercially prepared for clinical application as salts such as berberine chloride or berberine sulphate.

**Berberine pharmacokinetics**

Berberine has low bioavailability and shows poor absorption through the gut wall (<5%) and bowel P-glycoprotein appears to contribute its poor absorption, actively expelling the alkaloid from the lumen mucosal cells.

In a rat noncompartamental model, unbound berberine is transported to bile through active transportation and it is metabolized by p450 enzyme system in liver, with phase I demethylation and phase II glucuronidation. Berberine has four main metabolites identified in rats: berberrubine, thalifendine, demethylerberberine, and jatrorrhizine, all of which have glucuronide conjugates. Intestinal bacterial flora takes a role in enterohepatic circulation of berberine and its conjugated metabolites. On the other hand, a very small amount of unchanged berberine is eliminated in urine.

As other alkaloids contained in *H. canadensis* extracts (ie, hydrastine and canadine), berberine may inhibit CYP2E1-like and CYP1A2. This inhibition is not related to a significant increase in pharmacological interaction since most available drugs are not metabolized by these enzymatic systems.

**Berberine antihyperlipidemic effects**

The metabolic effects of berberine have been widely investigated during the last years. In lipid metabolism, the lipid-lowering effect of berberine appears to be mainly due to stabilization of hepatic LDL-C receptor (LDLR) by an extracellular signal-regulated kinase (ERK)-dependent pathway and also by increasing transcriptional activity of LDLR promoter by a c-Jun N terminal kinase (JNK) pathway. Besides, in 3T3L1 cells leptin, transcription factors like sterol regulatory element binding protein-1c (SREBP-1c) and CCAAT enhancer-binding protein-α (C/EBP-α), peroxisome-proliferator activated receptor-γ (PPAR-γ), fatty acid synthase, acetyl-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA synthase, and lipoprotein lipase are reduced by berberine treatment. Moreover, in addition to LDLR upregulation, berberine activates 5’ adenosine monophosphate (AMP) kinase (AMPK), while blocking the mitogen-activated protein kinase (MAPK)/ERK pathway, resulting in inhibition of lipid synthesis: its action on AMPK is eliminated by MEK inhibitors, suggesting a link between these two pathways (Figure 2).

In rodents, berberine has additive effects to nutrients inhibiting the cholesterol absorption from the bowel such as phytosterols (administered at the dosage of 100 mg/kg body weight), or to drugs inhibiting the liver cholesterol synthesis such as simvastatin (administered at the dosage of 6 mg/kg/day).

The antihyperlipidemic effects of berberine has also been confirmed in humans by some small clinical trials. Kong and
colleagues evaluated the effects of 500 mg berberine twice a day in a hyperlipidemic group of 32 Asian patients without any other drug use for three months and compared the results with 11 patients using placebo. Berberine significantly reduced the total cholesterol by 29%, triglycerides by 35%, and LDL-C by 25%. These results have been then confirmed in a larger trial carried out on 116 hyperlipidemic type 2 diabetic patients randomized to treatment with berberine 0.5 g thrice daily or placebo. Beyond a similar decrease in plasma lipids, the berberine-treated patients also experienced a significant decrease in glycohemoglobin, fasting and two-hour postprandial glucose levels compared with the placebo group.

Moreover, the antihyperlipidemic effect of berberine was observed to be synergistic with other nutraceuticals inhibiting cholesterol synthesis such as monakolins and policosanols. In a small clinical trial carried out on 40 Caucasian hyperlipidemic subjects randomized to berberine alone 500 mg/day or berberine 500 mg associated with policosanol 10 mg and red yeast extract 3 mg/day for four weeks, the reduction in triglycerides was 26% in the combination group and 22% in the berberine group, and reduction of LDL-C was 20% in the berberine group and 25% in the combination group.

**Effects of berberine on insulin resistance and fatty acids metabolism**

Beyond a direct and impressive effect of berberine on lipid metabolism, recent preclinical and clinical evidence suggest that it has also a strong impact on glucose homeostasis.

In fact, in cultured human liver cells and rat skeletal muscle, berberine increases insulin receptor mRNA expression through protein kinase C-dependent activation of its promoter.

It has been observed in cultured cells that berberine acts as an insulin-sensitizing agent, therefore its activity has been compared with metformin in different animal models. In a rat model of type 2 diabetes, berberine showed better fasting plasma glucose and LDL-C lowering and better homeostasis...
model assessment of insulin resistance (HOMA-IR) than metformin by a mechanism involving retinol binding protein-4 (RBP-4) and glucose transporter-4 (GLUT-4). However, in another study, berberine was not inferior to metformin as an insulin-sensitizer. It is possible that berberine does not act simply as an insulin-sensitizing agent, but that it may also interact directly with the pancreas. In fact, in streptozocin-induced diabetic rats, berberine administered at the doses of 120 mg/kg/day for five weeks was associated to an increase in glucagon-like peptide-1 (GLP-1) levels in plasma and intestine, in plasma insulin levels, and in the number of pancreatic beta cells. Furthermore, berberine inhibits sucrose and maltase activity similarly to acarbose, and since berberine has low bioavailability, its antihyperglycemic effects may be related to its intestinal actions.

Some evidence suggest that berberine also acts as a secretagogue agent which was demonstrated in diabetic rats where the this effect was compared with that of the sulphonylurea glibenclamide. In this test, berberine enhances glucose-stimulating insulin secretion in a dose-dependent manner, increasing both mRNA and protein expressions of hepatic nuclear factor 4α, and glycokinese activity, providing insulinotropic effect different from sulfonylureas. A dose-dependent insulin secretory effect was also observed by other authors, together with a favorable impact on plasma lipid levels. However, contrasting results are available since no secretagogue action in the betaTC3 cell line was observed, while a recent study observed that berberine acutely inhibits insulin secretion in MIN6 cells and rat islets. It is more probable that berberine has a protective effect for diabetes through increasing beta cell regeneration, antioxidant enzyme activity, and decreasing lipid peroxidation.

Other mechanisms of action have also been suggested to explain the complex berberine effect on glucose homeostasis. Some preclinical evidence shows that berberine inhibits mitochondrial function by inhibition of mitochondrial respiratory complex I, stimulation of glycolysis, activation of AMPK pathway, suppression of adipogenesis, antiobesity effects, and induction of LDLR expression. These are important mechanisms for insulin resistance and lipid metabolism.

In the 3T3-L1 adipocytes model of insulin resistance, berberine reverses 1 kB kinase beta (IKKbeta) Ser(181) and insulin receptor substrate 1 (IRS-1) Ser(307) phosphorylation and improves insulin-stimulated glucose transport and reverses free fatty acid (palmitic acid in this study)-induced insulin resistance. However, in another study carried out on the same cell lines, berberine did not augment either IRS-1, nor insulin receptor thyrosine phosphorylation, but it increased GLUT-4 levels in both normal and insulin-resistant cells and AMPK activity which is related to GLUT-1-mediated glucose uptake. Inhibition of mitochondrial glucose oxidation by berberine and increased AMP/adenosine triphosphate (ATP) ratio causes AMPK activation and glycolysis stimulation.

Therefore, Zhou and colleagues showed that, unlike insulin, berberine-induced glucose uptake of 3T3L1 adipocytes is not inhibited by phosphatidylinositol 3-kinase inhibitor or p38 MAPK inhibitor. Berberine does not induce Akt phosphorylation in opposition to insulin, but its action is totally inhibited by the thyrosine kinase inhibitor genistein. Finally, berberine increases AMPK and acetyl CoA carboxylase phosphorylation. Since the berberine-induced glucose uptake is inhibited both by AMPK inhibitor (compound C) and p38 MAPK inhibitor (SB202190), berberine uses an AMP–AMPK–p38 MAPK pathway and this may account also for its antihyperlipidemic effects. Berberine increases PPAR-α/Δ expression and reduced PPAR-γ expression in liver of diabetic rat to near control expression. In cellular models, the decrease in PPAR-γ mRNA transcription is associated with an inhibition of the adipocyte differentiation. This global action on the modulation of PPARs could at least partly explain the broad range of berberine metabolic activities on glucose and lipid metabolism. The effects of berberine on glucose metabolism are summarized on Figure 3.

Beyond the large preclinical literature, data on human glucose metabolism are really preliminary. However, in a recent study carried out on subjects affected by type 2 diabetes, the assumption of berberine 500 mg three times a day was associated with a significant reduction in hemoglobin-α1 (HbA1) (−2%), fasting plasma glucose (−44%), postprandial glucose (−45%), fasting plasma insulin (−28%), and HOMA-IR index (−44.7%). In this study, berberine also significantly reduced plasma total and LDL-C levels.

### Vascular and antihypertensive effects of berberine

Vasorelaxant effects of berberine have been observed in different rat models. At low concentrations (<1 × 10⁻⁶ M), berberine-mediated aortic relaxation appears to be dependent on endothelium, but at higher concentrations appears to be independent of intact endothelium. So, it is probable that berberine acts both on endothelium and underlying smooth muscle cells. Other mechanisms suggested to be involved in the vasorelaxant effect of berberine are...
an angiotensin-converting enzyme (ACE) inhibitory effect and direct release of NO/cGMP from rat aortic rings, \( ^{50} \) \( \alpha_1 \)-adrenoreceptor antagonistic action in rat and rabbit aorta, \( ^{51} \) increased sensitivity to the acetylcholine action, \( ^{46} \) activation of K+ channels, and the inhibition of intracellular calcium release, blocking of L-type calcium channels. \( ^{52} \) Berberine increases expression of endothelial nitric oxide synthase (eNOS) mRNA and inhibits expression of inducible nitric oxide synthase (iNOS) mRNA in gastric tissue also in studies on ethanol-induced gastric ulcer in mice. \( ^{53} \) In isolated rat thoracic aorta, prior exposure to berberine attenuated angiotensin-1-induced contraction and increases NO and cGMP 1 with a half maximal inhibitory concentration (IC\(_{50}\)) value of 42 mg/mL (125 \( \mu \)M). \( ^{54} \)
Activation of tetratopentammonium-, 4-aminopyridine- and Ba2+-sensitive K+ channels, inhibition of intracellular Ca2+ release from caffeine-sensitive pools, or a direct relaxant effect, are also likely responsible for the berberine-induced endothelium-independent relaxation.55

The vasodilator effects of berberine are not observed at low concentrations (below 1 × 10−6 M) on methylene blue-pretreated rat aorta, but aortic relaxation was observed at higher concentrations irrespective of such nitric oxide inhibitors.56

Blood pressure increase could also be prevented by a nephroprotective effect. In a model of rat diabetic nephropathy, oral administration of berberine at 200 mg/kg/day doses for 12 weeks improved the kidney-to-body weight ratios, glomerular area and volume, kidney tests (serum creatinine, serum uric acid, serum urea, urine protein for 24 hours), and increased serum superoxide dismutase and decreased malondialdehyde and aldose reductase levels.57

Berberine also has some vascular-protecting action that could preserve the arterial functionality from damage and keep the vessels more reactive and elastic. In fact, berberine inhibits platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell growth via activation of AMPK/p38/p21(Cip1) signaling while activating Ras/Rac1/Cyclin D/Cdk5, and suppressing PDGF-stimulated migration by Rac1 and Cdc42 inhibition, finally causing antiproliferative and antimigratory effects.58 In rat glomerular mesangial cells, berberine inhibits fibronectin and collagen synthesis partly via a p38 MAPK pathway.59 It also prevents the migration and regrowth of smooth muscle cells to the mechanically traumatized site by inactivating the MAPK/ERK/early growth response gene 1 (Egr1) signaling pathway, decreasing Erg1, cFos, cyclin-D, and platelet-related growth factor A (PDGF-A) levels.60 Activation of ERK1,2 pathway was also demonstrated by its inhibition of lysophosphatidylcholine-stimulated vascular smooth muscle cell proliferation and migration.61

Concerning human data, in a study carried out on 20 volunteers, 400 mg berberine three times a day for a month induced upregulation of the number and function of erythrocyte progenitor cells due to NO production.62 One month’s treatment with berberine (400 mg/day, three times a day) in 15 healthy volunteers induced mobilization of circulating endothelial progenitor cells with CD34/KDR double positivity in small arteries.63

**Direct effects of berberine on heart**

Berberine does not have only indirect myocardium protective effects by modulating lipid metabolism, glucose homeostasis, and blood pressure, but it also directly acts on the heart at different levels.

In fact, berberine has a sympathetic activity-modulated effect on myocardium. In rats with experimentally induced cardiac hypertrophy by suprarenal aortic constriction, berberine decreased plasma noradrenaline and adrenaline levels and adrenaline in ventricular tissue, improved cardiac contractility with a shortened time to reach the maximum rate from beginning of contraction and reduced the size of left ventricular myocardium.64,65 In a dog ischemic heart failure model, intravenous berberine administration increased cardiac output, decreased left ventricular end diastolic pressure and systemic vascular resistance.66 This activity was also confirmed in other animal models.69

Berberine increased high energy phosphate in heart failure and prevented ventricular fibrillation due to its effects on potassium channels,57,58 increased intracellular calcium,69 suppressed delay of depolarization partly due to sodium influx.70 Berberine blocked ATP-sensitive and voltage-sensitive K′(ATP) channels and caused shortening of action potential duration and effective refractory period, thus it mainly has a class III antiarrhythmic effect as shown in different animal models.71

Berberine reduced creatine phosphokinase release in reoxygenation period in rat myocytes and decreased the morphologic features related with myocardial injury, which reduced lactate dehydrogenase and methylene dioxyamphetamine levels and the apoptosis rate.72

Examination of hemodynamic parameters in humans reveals similar results with increased cardiac index, increased left ventricular ejection fraction, decreased systemic and pulmonary vascular resistance and left ventricular end-diastolic pressures.73 In a clinical trial carried out on chronic heart failure patients, berberine decreased frequency and complexity of ventricular premature complexes and increased the left ventricular ejection fraction.74 In 24–48-hour ambulatory monitoring of 100 patients with ventricular tachyarrhythmia, berberine caused 50% or greater reduction in ventricular premature contractions in 62% of patients and 90% or more reduction in 38% of patients.75

**Other berberine activities with potential relevance in cardiovascular disease prevention**

Some studies show that berberine has a significant antiplatelet effect,76 explained by inhibition of arachidonic acid metabolism and calcium influx,77 but also by a partial agonistic effect on platelet α2 adrenoreceptors.78 Berberine inhibited thromboxane
synthesis induced by collagen, adenosine diphosphate and arachidonic acid, and it might inhibit arachidonic acid metabolism in platelets and endothelial cells.\textsuperscript{71} On the other hand, recent evidence suggests that berberine can also have prothrombotic effect-enhancing tissue factor activity.\textsuperscript{78}

Another pharmacological effect of berberine that could be relevant in atherosclerosis prevention is its anti-inflammatory effect. Berberine probably inhibits cyclooxygenase-2 (COX-2) via the ERK1/2 signaling pathway and, in high doses, via the JNK pathway in human peripheral blood monocytes.\textsuperscript{79} However, the anti-inflammatory effects of berberine may also be mediated through nuclear factor-\textgamma B activation pathway inhibition which modulates the transcription of genes codifying for COX-2, matrix metalloprotease-9, cyclin D-1, and survivin.\textsuperscript{80} Moreover, berberine inhibits matrix metalloprotein-9 and interleukin-6 (IL-6) in normal human keratocytes and shows anti-inflammatory effects on skin.\textsuperscript{81} Berberine downregulated the mRNA of tumor necrosis factor-\textalpha, IL-2, C-reactive protein, and haptoglobin in 3T3L1 adipocytes.\textsuperscript{82} Similar results have also been observed in macrophages.\textsuperscript{83} This effect could be mediated by an activation of PPAR-\gamma mediated by an increase in adipophilin, but most researchers suggest that Berberine acts more as a PPAR-\gamma inhibitor than as an activator, at least in adipocytes, hepatocytes, and retinal cells. This difference remains to be explained.

In rabbit corpus cavernosum smooth muscle cell cultures, berberine inhibits the damaging effects of H\textsubscript{2}O\textsubscript{2} by increased cell viability, increased nitric oxide, and superoxide dismutase (SOD) activity, decreased lactate dehydrogenase release and the malondialdehyde content of the tissue.\textsuperscript{84} The antioxidant effect of berberine has also been demonstrated in human umbilical endothelial cells, probably in relative electrophoretic mobility of oxidized-LDL, fragmentation of apolipoprotein B and malonyldialdehyde production, inhibition of caspase 3 activation and cytochrome C release.\textsuperscript{85} Dose-dependent increase in SOD by berberine was then confirmed in rats together with reduction in \textalpha-smooth muscle actin (\textalpha-SMA) and transforming growth factor-\beta (TGF-\beta) liver steatosis and necrosis in a rat liver fibrosis model.\textsuperscript{86} Other studies on rodent hepatocytes showed reduced oxidative stress, higher level of DNA repair induction, reduced histopathological evidence of tissue injury with berberine treatment.\textsuperscript{87} This effect, associated to the metabolic ones, could suggest its potential usefulness in the management of the nonalcoholic steatohepatitis (NASH), an emergent cardiovascular disease risk factor.

**Berberine tolerability and safety**

The median lethal dose (LD\textsubscript{50}) of berberine sulfate is 25 mg/kg in mice, but for Berberis vulgare, is moderately high (LD\textsubscript{50} = 2.6 ± 0.22 g/kg bodyweight in mice).\textsuperscript{88} These data support the use of highly purified and concentrated berberine formulation only.

Standard doses of berberine are usually well tolerated and eventual adverse events are rare and mild. On the contrary, high doses have been associated with arterial hypotension, dyspnea, flu-like symptoms, gastrointestinal discomfort, constipation, and cardiac damage.\textsuperscript{89} The most studied side effects are those in the gastrointestinal system. Berberine and derivatives can produce gastric lesions.\textsuperscript{90} As shown by determination of small intestinal transit time (SITT) measurements by sorbitol and breath hydrogen test (BHT), berberine delays SITT, and this may account for a part of its gastrointestinal side effects (but also of its anti diarrheal one).\textsuperscript{90}

The main safety issue of berberine involves the risk of some pharmacological interaction. In fact, berberine displaces bilirubin from the albumin about 10-fold more than phenylbutazone, thus any herb containing large amounts of berberine should be avoided in jaundiced infants and pregnant woman.\textsuperscript{91} Berberine displaces warfarin, thiopental, and tolbutamide from their protein-binding sites, increasing their plasma levels.\textsuperscript{92}

Berberine can markedly increase blood levels of cyclosporine A because of CYP3A4 and P-glycoprotein inhibition in the liver and gut wall, respectively, and because of an increase in gastric-emptying time causing increased cyclosporine A bioavailability and reduced metabolism.\textsuperscript{93} In renal transplant recipients who take cyclosporine 3 mg/kg twice daily, the coadministration of berberine (0.2 g/day for three times a day for three months) increases the mean cyclosporine A area under the curve by 34.5\% and its mean half-life by 2.7 hours.\textsuperscript{94}

In rats, P-glycoprotein and organic cation transport inhibit active berberine efflux since coadministration of berberine and cyclosporine (a P-glycoprotein inhibitor) or quinidine (both an organic cation transport and P-glycoprotein inhibitor) at the same dosage significantly decreased the berberine amount in bile. In addition, berberine was metabolized in the liver with phase I demethylation and phase II glucuronidation, as identified by high = pressure liquid chromatography/tandem mass spectrometry. The phase I metabolism of berberine was partially reduced by SKF-525A (proadifen, a cytochrome P450 inhibitor) treatment, but the phase II glucuronidation of berberine was not obviously affected by probenecid 1 glucuronidation inhibitor).\textsuperscript{95} Berberine is also a substrate of the organic cation transporter 1 (OCT1, SLC22A1) in the basolateral membrane and MDR1
P-glycoprotein (MDR1 P-gp, ABCB1), an ATP-dependent efflux pump for organic cations, in the apical membrane.\textsuperscript{95}

Moreover, it was observed with flow cytometry that a 24-hour berberine treatment upregulated the multidrug-resistant transporter (P-gp-170) expression in two oral (KB, OC2), two gastric (SC-M1, NUGC-3), and two colon (COLO 205, CT 26) cancer cell lines. Decreased retention of rhodamine 123 was observed in berberine-treated cells as compared to vehicle control. Pretreatment of cells with 32 microM berberine for 24 hours prior to Paclitaxel treatment resulted in increased viability as compared to that of Paclitaxel-treated cells. Moreover, pretreatment of cells with berberine prior to Paclitaxel blocked the Paclitaxel-induced cell cycle responses and morphological changes. These results together suggest that berberine modulated the expression and function of P-gp-170 that leads to reduced response to Paclitaxel in digestive track cancer cells.\textsuperscript{96}

Even if the main mechanism of pharmacological interaction of berberine involve CYP3A4 and intestinal P-glycoprotein, it also inhibits CYP1A1, so potentially interacting with drugs metabolized by this cytochrome isophorm as well.\textsuperscript{97}

Conclusion
A large part of the literature on berberine is difficult to access since it was published in Chinese and this limited our possibility to directly access to some interesting scientific data. However, on the basis of the evidence cited above, we can conclude that numerous preclinical studies and some well-carried out clinical trials strongly support the potential use of berberine as a powerful insulin-sensitizing agent with relevant antihyperlipidemic effects and vascular protective action. Further long-term randomized clinical trials have to be carried out in order to better delineate the clinical indications and the safety profile of berberine.

Disclosures
The authors report no conflicts of interest in this work.

References


